Onychomycosis: Treatment, quality of life, and economic issues

American Journal of Clinical Dermatology

Volumn 1, Issue 1, 2000, Pages 19-26

  Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMICS; HUMAN; ONYCHOMYCOSIS; QUALITY OF LIFE; REVIEW;

HUMANS; ONYCHOMYCOSIS; QUALITY OF LIFE;

EID: 0033767297     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001010-00002     Document Type: Review

References (72)

1. Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263-74
2. Kemna ME, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996 Oct; 35 (4): 539-42
3. De Donker PRG, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997 Feb; 36 (2): 173-7
4. Kam KM, Au WF, Wong PY, et al. Onychomycosis in Hong Kong. Int J Dermatol 1997 Oct; 36 (10): 757-61
5. Mercantini R, Marsella R, Moretto D. Onychomycosis in Rome, Italy. Mycopathologia 1996; 136 (1): 25-32
6. Ginter G, Rieger E, Heigl K, et al. Increasing frequency of onychomycosis - is there a change in the spectrum of infectious agents? Mycoses 1996; 39 Suppl. 1: 118-22
7. Velez A, Linares MJ, Fenandez-Roldan JC, et al. Study of onychomycosis in Cordoba, Spain: prevailing fungi and pattern of infection. Mycopathologia 1997; 137 (1): 1-8
8. Summerbell RC. Epidemiology and ecology of onychomycosis. Dermatology 1997; 194 Suppl. 1: 32-6
9. Ellis DH, Marley JE, Watson AB, et al. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatol 1997; 194 Suppl. 1: 40-2
10. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994 Sep; 31 (3): S21-5
11. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15
12. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada -A multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783-7
13. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992 Feb; 126 Suppl. 39: 23-7
14. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997 Sep; 133(9): 1172-3
15. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995 Nov; 133 (5): 699-703
16. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997 Mar; 36 (3): 395-402
17. Zienicke HC, Korting HC, Likacs A, et al. Dermatophytosis in children and adolescents: epidemiological, clinical, and microbiological aspects changing with age. J Dermatol 1991 Aug; 18 (8): 438-46
18. Philpot CM, Shuttleworth D. Dermatophyte onychomycosis in children. Clin Exp Dermatol 1989 May; 14 (3): 203-5
19. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996 Sep; 35 (3): S2-5
20. Odom RB. Common superficial fungal infections in immunosuppressed patients. J Am Acad Dermatol 1994 Sep; 31 (3): S56-9
21. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997 Dec; 87 (12): 546-50
22. Gregory N. Special patient populations: onychomycosis in the HIV-positive patient. J Am Acad Dermatol 1996 Sep; 35 (3): S13-6
23. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997 May; 136 (5): 786-9
24. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence of onychomycosis in diabetics: a North American survey. Poster presented at the Fifth International Summit on Cutaneous Antifungal Therapy; 1998 Jun 15-17; Singapore
25. US Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA; 1997
26. US Department of Health and Human Services, Centers for Disease Control and Prevention. Diabetes. A Serious Public Health Problem. At-A-Glance. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA; 1998
27. Drake LA. Impact of onychomycosis on quality of life. J Am Podiatr Med Assoc 1997 Nov; 87 (11): 507-11
28. Shuster S, Fisher GH, Harris E, et al. The effect of skin disease on self image. Br J Dermatol 1978 July; 99 Suppl. 16: 18-9
29. Wessely SC, Lewis GH. The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry 1989; 155: 686-91
30. Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998 May; 38 (5): S64-8
31. Lubeck DP, McNulty PP, Fifer SK, et al. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341-8
32. Schein JR, Gause D, Stier DM, et al. Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc 1997 Nov; 87 (11): 512-9
33. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754-6
34. Goldsmith H. Practice management and managed-care issues in onychomycosis. J Am Podiatr Assoc 1997; 87 (11): 532-9
35. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-9
36. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38 (5): 702-4
37. Data on file, Grifulvin V® (griseofulvin), Ortho Dermatologics, Skillman, NJ
38. Data on file, Nizoral® (ketoconazole), Janssen Pharmaceutica, Titusville, NJ
39. Del Rosso JC, Gupta AK. Oral antifungal agents: recognition and management of adverse reactions. Today's Therapeutic Trends 1997; 15 (2): 75-84
40. Del Rosso JC. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 1997; 97 (6): 339-46
41. Data on file, Diflucan® (fluconazole), Pfizer, Inc, New York, NY
42. Data on file, Sporanox® (itraconazole), Janssen Pharmaceutica, Titusville, NJ
43. Data on file, Lamisil® (terbinafine hydrochloride), Novartis Pharmaceuticals Corporation, East Hanover, NJ
44. Del Rosso JC, Gupta AK. The spectrum of utility of oral antifungal agents: from the petri dish to the patient. Today's Therapeutic Trends 1997; 15 (3): 179-89
45. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl. 1: 67-87
46. Matthieu L, De Donker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-6
47. De Donker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37 (6): 969-74
48. De Donker P, Gupta AK, Del Rosso JC, et al. Update on the safety of itraconazole pulse therapy in onychomycosis. Poster presentation at the American Academy of Dermatology Academy '98, Chicago, IL
49. National Institute on Aging. Progress Report on Alzheimers Disease 1997. Bethesda, MD: National Institute on Aging; 1997
50. Rosenbach ML, Schneider JE. The burden of onychomycosis in the Medicare population. Health Economic Research Inc., Sandoz Pharmaceuticals Corporation. On file.
51. American Podiatric Medical Association. 1997 Diabetes Survey. Statistical results. J Am Podiatr Assoc 1997; 87 (12): 575-83
52. US Department of Health and Human Services, Food and Drug Administration. Dermatological Drugs Advisory Committee Meeting #40 [transcript]. Center for Drug Evaluation and Research. 1994 Sep 23, Rockville, MD
53. Sinclair R. What is the cost of onychomycosis? Australas J Dermatol 1998; 39 (2): 131-2
54. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl. 43: 32-4
55. Marchetti A, Tak Piech C, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757-77
56. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998 Feb; 13 (2): 243-56
57. Van Doorslaer EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996;193: 239-44
58. Bootman JL. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 1998 May; 38 (5): S69-72
59. Gupta AK, De Donker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-8
60. Abdel-Rahman SM, Marcucci K, Boge T, et al. Inhibition of cytochrome P4502D6 (CYP2D6) by terbinafine (Ter) in vitro. Clin Pharmacol Ther 1998; 65 (2): 135
61. Abdel-Rahman SM, Gotschall RR, Kauffman RE, et al. Inhibition of cytochrome P4502D6 (CYP2D6) by terbinafine (Ter) in vivo. Clin Pharmacol Ther 1998; 65 (2): 135
62. Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol 1998; 138 (3): 529-32
63. Gupta AK. Terbinafine: an update. J Am Acad Dermatol 1997; 37 (6): 979-88
64. Gupta AK, Sibbald RG, Knowles SR. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36 (5): 858-62
65. Kempinaire A, De Raeve L, Merckx M. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol 1997; 37 (4):653-5
66. Carstens J, Wendelboe P, Søgaard H, et al. Toxic epidermal necrolysis and ery thema multiforme following therapy with terbinafine. Acta Derm Venereol (Stockh) 1994 Sep; 74 (5): 391-2
67. Gupta AK, Gonder JR, Shear NH, et al. The development of green vision in association with terbinafine therapy. Arch Dermatol 1996; 132: 845-6
68. Beutler M, Hartmann K, Kuhn M, et al. Taste disorders and terbinafine. BMJ 1993; 307: 26
69. Back D. Loss of taste and terbinafine. Lancet 1992; 340: 252
70. Juhlin L. Loss of taste and terbinafine. Lancet 1992; 339: 1483
71. Agarwal K, Manas D, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med 1999; 340 (16): 1292-3
72. Nolting SK, Sanchez Carazo J, De Boulle K, et al. Oral treatment schedules for onychomycosis: a study of patient preference. Int J Dermatol 1998; 37: 454-6